Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-09
2000-10-17
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 3144
Patent
active
061332534
ABSTRACT:
The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula I: ##STR1## or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula I above which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.
REFERENCES:
patent: 4592866 (1986-06-01), Cale, Jr.
patent: 4643995 (1987-02-01), Engel et al.
patent: 4705853 (1987-11-01), Cale, Jr.
patent: 4929625 (1990-05-01), Cliffe et al.
patent: 4946836 (1990-08-01), Engle et al.
patent: 4956359 (1990-09-01), Taylor, Jr. et al.
patent: 5037841 (1991-08-01), Schoehe et al.
patent: 5472958 (1995-12-01), Gunn et al.
patent: 5629325 (1997-05-01), Lin et al.
Abreo, M. A. et al.; Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors; J. Med. Chem. 39:817-825 (1996).
Akaike, A. et al.; Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity, Brain Research, 644:181-187 (1994).
Badio, et al.; Antinociceptice Effects of the Aklaloid Epibatidine: Further Studies on Involvement of Nicotine Receptors; Drug Development Research; 36:46-59 (1995).
Berge, S.M. et al.; Pharmaceutical Salts; Journal of Pharmaceutical Sciences; 66:1-19 (1977).
Brioni et al.; "In Vivo' Profile of Novel Nicotinic Ligands with CNS Selectivity"; Medicinal Chemistry Research; vol. 6; No. 7/8, pp. 487-510 (1996).
Burger, Alfred Medicinal Chemistry; Wiley-Interscience; New York; (1970).
Carty, T.J. and Marfat, A., Cox-2 Inhibitors. "Potential for Reducing NSAID side-effects in treating inflammatory diseases"; Emerging Drugs: The Prospect for Improved Medicines; Ashley Publications Ltd.; pp. 391-411 (1996).
Cherney, N.I., "Opioid Analgesics, Comparative Features and Prescribing Guidelines"; Drugs 51:713-737, (1996).
Clark, J.H. and Macquarrie, D.J.; The Synthesis of Organfluorine Compounds Using Potassium Fluoride-Tetraphenylphosphonium Bromide Systems; Tetrahedron Letters; vol. 28; No. 1; pp. 111-114 (1987).
Dray et al.; Pharmacology of chronic pain; Trends in Pharmacological Sciences; 15:190-197 (1994).
Dray, A. and Urban L.; "New Pharmacological Strategies for Pain relief"; Annual Review of Pharmacology and Toxicology; 36:253-280 (1996).
Dirig, D.M. and Yaksh, T.L.; Pain; 62:321-328 (1995).
Effenberger et al.; Chem Ber.; 125:1131-1140 (1992).
Hargreaves et al; Pain; 32:77-88 (1988).
Kim and Chung; Pain; 50:355-363 (1992).
Koch, V. and Schnatterer, S.; Synthesis; 497-501 (1990).
Lukas, R.J.; J. Pharmacol. Exp. Ther.; 265:294-302 (1993).
Marin, P. et al.; Neuroreport; 5:1977-1980 (1994).
Martin, E.J. et al.; Drug Dev. Res.; 31:135-141 (1994).
Miyoshi et al.; Chem. Lett.; 5-6 (1973).
Odashima et al.; Bull. Chem. Soc. Japan; 66:797-803 (1993).
Pabreza et al; Molecular Pharmacol.;39:9 (1990).
Rodebaugh and Cromwell; Journal Het. Chem.; 6: 435 and 993 (1969).
Sheen, K. and Chung, J.M.; Brain Res.; 610:62-68 (1993).
Silverman, Richard B.; The Organic Chemistry of Drug Design and Drug Action; Academic Press, Inc. (1992).
Sugano and Miyoshi; Bull. Chem. Soc. Japan, 46; 669 (1973).
Sullivan, et al.; (+)-Epibatidine Elicits a Diversity of In Vitro and In Vivo Effects Mediated by Nicotinic Acetylcholine Receptors, Journal. of Pharm. And Experimental Therapeutics; vol. 271; No. 2; pp. 624-631.
Sullivan, et al.;; "A-85380 [3-(2(S)-Azetidinylmethoxy) Pyridine]: In Vitro Pharmacological Properties of a Novel, High Affinity .alpha.4.beta.2 Nicotinic Acetylcholine Receptor Ligand"; Neuropharmacology; vol. 35; No. 6; pp. 725-734 (1996).
Sullivan, et al.; Epibatidine: Pharma. Properties of a Novel Nicotinic Acetylcholine Receptor Agoists and Analgesic Agent, CNS Drug Reviews; vol. 2; No. 1; pp. 21-39.
Tanner and Somfai; Tetrahedron Lett.; 28:1211-1214 (1987).
Tomioko, K. et al.; Stereoselective Reactions XIX. Asymmetric Dihydroxylation of Olefins by Employing Osmium Tetroxide-Chiral Amine Compleaxes; Chem. Pharm. Bull.; 38:2133-2135 (1990).
Tjolsen et al.; Pain; 51:5-17 (1992).
Winter, C.A. et al.; Proc. Soc. Exp. Biol. Med.; 111:544 (1962).
Arneric Stephen P.
Bai Hao
Dart Michael J.
Ehrlich Paul P.
Holladay Mark W.
Abbott Laboratories
Kifle Bruck
Pope Lawrence S.
Shah Mukund J.
LandOfFree
3-Pyridyl enantiomers and their use as analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-Pyridyl enantiomers and their use as analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-Pyridyl enantiomers and their use as analgesics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-469047